%PDF-1.4
%
70 0 obj
<>
endobj
67 0 obj
<>
endobj
129 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T14:20:15Z
2024-03-29T04:14:08-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T04:14:08-07:00
application/pdf
Heather
2001-727.july02
uuid:f3367f22-1dd1-11b2-0a00-ed08275d6100
uuid:f3367f25-1dd1-11b2-0a00-aa0000000000
endstream
endobj
56 0 obj
<>
endobj
57 0 obj
<>
endobj
71 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
20 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
33 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
46 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
155 0 obj
[159 0 R]
endobj
156 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
55 54 m
559 54 l
54 54 m
558 54 l
S
BT
/CS0 cs 0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:8)Tj
0 Tw -46.2952 -0.0313 Td
(1652)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 57.75 407.5 -10.83 re
f*
0.5 w
102.25 57.75 407.5 -10.83 re
S
BT
0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61.6667 713.196 Tm
[(7.)-625.1 (Malfait )54.8 (AM, )17.7 (W)39.7 (illiams RO, Malik )54.8 (AS, Maini RN, Feldman M.)]TJ
0 Tc 1.5 -1.25 Td
(Chronic relapsing homologous collagen-induced arthritis in DBA/1)Tj
0 -1.25 TD
(mice as a model for testing disease-modifying and remission-)Tj
T*
[(inducing therapies. )54.9 (Arthritis Rheum 2001;44:1215-24.)]TJ
-0.00011 Tc -1.5 -1.25 Td
[(8.)-625.1 (Kong )36.8 (YY)128.8 (, )36.8 (Y)100 (oshida H, Sarosi I, et al. OPGL)-238.2 (is a key regulator of)]TJ
0 Tc 1.5 -1.25 Td
(osteoclastogenesis, lymphocyte development and lymph-node)Tj
T*
[(or)17.8 (ganogenesis. Nature 1999;397:315-23.)]TJ
-1.5 -1.25 Td
[(9.)-625 (V)111.1 (an Rijthoven )54.8 (A)80.1 (W)110.8 (AM, Dijkmans BAC, Goei )17.7 (The HS, et al.)]TJ
1.5 -1.25 Td
[(Cyclosporin treatment for rheumatoid arthritis: )54.9 (A)-219.8 (placebo)]TJ
T*
[(controlled, double blind, multicentre study)64.9 (. )54.8 (Ann Rheum Dis)]TJ
0 Tw T*
(1986;45:726-31.)Tj
0.0249 Tw -2 -1.25 Td
[(10.)-625 (Dougados M, )54.8 (A)92 (wada H, )54.8 (Amor B. Cyclosporin in rheumatoid)]TJ
2 -1.25 Td
(arthritis: a double-blind, placebo-controlled study in 52 patients.)Tj
T*
(Ann Rheum Dis 1988;47:127-33.)Tj
-1.9631 -1.25 Td
[(1)36.9 (1.)-625 (T)34.9 (ugwell PC, Bombardier M, Gent M, et al. Low dose cyclosporin in)]TJ
1.9631 -1.25 Td
[(rheumatoid arthritis: )54.9 (A)-219.8 (pilot study)64.9 (. J Rheumatol 1987;14:1)36.9 (108-14.)]TJ
-0.00011 Tc -2 -1.25 Td
[(12.)-625.1 (Forre O and the Norwegian )54.8 (Arthritis Study Group. Radiologic)]TJ
0 Tc 2 -1.25 Td
(evidence of disease modification in rheumatoid arthritis patients)Tj
T*
(treated with cyclosporine: results of a 48-week multicenter study)Tj
T*
[(comparing low-dose cyclosporine with placebo. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1994;37:1506-12.)Tj
0.0249 Tw -2 -1.25 Td
[(13.)-625 (T)34.9 (ugwell P)110.8 (,)0.1 ( Pincus )17.7 (T)74 (, )36.8 (Y)100.1 (ocum D, et al. Combination therapy with)]TJ
2 -1.25 Td
(cyclosporine and methotrexate in severe rheumatoid arthritis. )Tj
T*
(N Engl J Med 1995;333:137-41.)Tj
-2 -1.25 Td
[(14.)-625 (Pasero G, Priolo F)79.8 (, Marubini E, et al. Slow progression of joint)]TJ
2 -1.25 Td
[(damage in early rheumatoid arthritis treated with cyclosporin )54.9 (A.)]TJ
T*
(Arthritis Rheum 1996;39:1006-15.)Tj
-0.00011 Tc -2 -1.25 Td
[(15.)-625.1 (Ferraccioli GF)79.7 (, Bambara LM, Ferraris M, et al. Ef)17.7 (fects of)]TJ
0 Tc 2 -1.25 Td
[(cyclosporine on joint damage in rheumatoid arthritis. )17.8 (The Italian)]TJ
T*
[(Rheumatologists Study Group on Rheumatoid )54.8 (Arthritis. Clin Exp)]TJ
T*
(Rheumatol 1997;15:S83-89.)Tj
-2 -1.25 Td
[(16.)-625 (Altman RD, Schif)17.8 (f M, Kopp EJ, and the Cyclosporine )54.8 (A)-219.8 (Study)]TJ
2 -1.25 Td
[(Group. Cyclosporine )54.8 (A)-219.8 (in rheumatoid arthritis: randomized, placebo)]TJ
T*
[(controlled dose-finding study)64.9 (. J Rheumatol 1999;26:2102-9.)]TJ
-0.00011 Tc -2 -1.25 Td
[(17.)-625.1 (Emmel EA, )17.7 (V)111 (erweij CL, Durand DB, Higgins KM, Lacy E,)]TJ
0 Tc 2 -1.25 Td
[(Crabtree GR. Cyclosporine )54.9 (A)-219.8 (specifically inhibits function of)]TJ
T*
[(nuclear proteins involved in )17.8 (T)-257.2 (cell activation. Science)]TJ
0 Tw T*
(1989;246:1617-20.)Tj
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(18.)-625.1 (Flanagan )17.7 (WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear)]TJ
0 Tc 2 -1.25 Td
[(association of a )17.8 (T)91.8 (-cell transcription factor blocked by FK506 and)]TJ
T*
[(cyclosporin )54.9 (A. Nature 1991;352:803-7.)]TJ
-2 -1.25 Td
[(19.)-625 (Cannon GW)91.8 (, McCall S, Cole BC, Radov LA, )17.7 (W)79.8 (ard JR, Grif)17.8 (fiths)]TJ
2 -1.25 Td
[(MM. Ef)17.8 (fects of gold sodium thiomalate, cyclosporin )54.8 (A,)]TJ
T*
(cyclophosphamide, and placebo on collagen-induced arthritis in)Tj
-0.02991 Tw T*
[(rats. Agents Actions )-54.9 (1993;38:240-6.)]TJ
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(20.)-625.1 (Arita C, Hotokebuchi )17.7 (T)73.9 (, Miyahara H, )54.8 (Arai K, Sugioka )36.8 (Y)129.1 (, Kaibara N.)]TJ
0 Tc 2 -1.25 Td
(Inhibition by FK506 of established lesions of collagen-induced)Tj
T*
(arthritis in rats. Clin Exp Immunol 1990;82:456-61.)Tj
-2 -1.25 Td
[(21.)-625 (W)39.8 (illiams RO, Mauri C, Mason LJ, et al. )17.8 (Therapeutic actions of)]TJ
2 -1.25 Td
(cyclosporine and anti-tumor necrosis factor alpha in collagen-)Tj
T*
[(induced arthritis and the ef)17.8 (fect of combination therapy)64.9 (. )54.9 (Arthritis)]TJ
T*
(Rheum 1998;41:1806-12.)Tj
-2 -1.25 Td
[(22.)-625 (Christians )17.7 (W)91.8 (,)0.1 ( Sewing KF)79.8 (. )54.8 (Alternative cyclosporine metabolic)]TJ
2 -1.25 Td
[(pathways and toxicity)64.9 (. Clin Biochem 1995;28:547-59.)]TJ
-0.00011 Tc -2 -1.25 Td
[(23.)-625.1 (Abel MD, )54.8 (Aspeslet LJ, Freitag DG, et al. Preclinical ef)17.7 (ficacy of a)]TJ
0 Tc 2 -1.25 Td
(novel calcineurin inhibitor: ISA)Tj
-0.00031 Tc 0 Tw 5.2 0 0 5.2 176.2335 160.556 Tm
(TX)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 183.1638 163.196 Tm
[(247 [abstract]. )54.8 (Am J )17.7 (T)34.8 (ransplant)]TJ
0 Tc -13.6871 -1.25 Td
(2001;1 Suppl 1:436.)Tj
-2 -1.25 Td
[(24.)-625 (Shapiro )54.8 (AMJ, Rajotte RJ, Lakey JR)59.8 (T)74 (, Bigam DL, Kneteman NM,)]TJ
2 -1.25 Td
[(Y)100.1 (atscof)17.8 (f R)54.9 (W)91.8 (. Prolonged islet allograft survival without toxicity)]TJ
-0.00011 Tc T*
(using ISA)Tj
-0.00031 Tc 0 Tw 5.2 0 0 5.2 106.0854 120.556 Tm
(TX)Tj
0 Tc 0.0249 Tw 8 0 0 8 113.0157 123.196 Tm
[(247, a novel calcineurin inhibitor [abstract]. )54.8 (Am J)]TJ
-4.9186 -1.25 Td
[(T)34.9 (ransplant 2001;1 Suppl 1:343.)]TJ
-0.00011 Tc -2 -1.25 Td
[(25.)-625.1 (Y)100 (atscof)17.7 (f R)54.8 (W)91.7 (, )54.8 (Abel MD, )54.8 (Aspeslet LJ, et al. )54.8 (A)-219.9 (novel calcineurin)]TJ
0 Tc 2 -1.25 Td
(inhibitor with minimal renal toxicity: ISA)Tj
-0.00031 Tc 0 Tw 5.2 0 0 5.2 208.6394 90.556 Tm
(TX)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 215.5697 93.196 Tm
(247 [abstract]. )Tj
0 Tc -17.7379 -1.25 Td
(J Rheumatol 2001;28 Suppl 63:109.)Tj
-0.00011 Tc 31 78.75 Td
[(26.)-625.1 (Abel MD, )54.8 (Aspeslet LJ, Freitag DG, et al. ISA)]TJ
-0.00031 Tc 0 Tw 5.2 0 0 5.2 484.4445 710.556 Tm
(TX)Tj
0 Tc 0.02499 Tw 8 0 0 8 491.3748 713.196 Tm
(247: a novel)Tj
-19.2135 -1.25 Td
[(calcineurin inhibitor with minimal renal toxicity [abstract]. )54.8 (Am J)]TJ
T*
[(T)34.9 (ransplant 2001;1 Suppl 1:437.)]TJ
-2 -1.25 Td
[(27.)-625 (Caccese RG, Zimmerman JL, Carlson RP)110.8 (. Bacterial)]TJ
2 -1.25 Td
(lipopolysaccharide potentiates type II collagen-induced arthritis in)Tj
T*
(mice. Mediators Inflamm 1992;1:273-9.)Tj
-2 -1.25 Td
[(28.)-625 (W)79.8 (ebb L, )17.8 (W)79.8 (almsley M, Feldmann M. Prevention and amelioration of)]TJ
2 -1.25 Td
(collagen-induced arthritis by blockade of the CD28 co-stimulatory)Tj
T*
(pathway: Requirement for both B7-1 and B7-2. Eur J Immunol)Tj
0 Tw T*
(1996;26:2320-8.)Tj
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(29.)-625.1 (Panayi GS, Corrigall )17.7 (VM, Pitzalis C. Pathogenesis of rheumatoid)]TJ
0 Tc 2 -1.25 Td
[(arthritis: )17.7 (The role of )17.7 (T)-257.2 (cells and other beasts. Rheum Dis Clin North)]TJ
T*
(Am 2001;27:317-34.)Tj
-0.00011 Tc -2 -1.25 Td
[(30.)-625.1 (Birsan )17.7 (T)73.9 (,)-0.1 ( Dambrin C, )17.7 (V)60 (illanueva JC, )36.8 (Y)100 (atscof)17.7 (f R)54.8 (W)91.7 (, Morris RE. Ex)]TJ
0 Tc 2 -1.25 Td
[(vivo evaluation of the immunosuppressive ef)17.8 (fect of the novel)]TJ
T*
(calcineurin inhibitor ISA)Tj
-0.00031 Tc 0 Tw 5.2 0 0 5.2 418.0374 560.556 Tm
(TX)Tj
0 Tc 0.02499 Tw 8 0 0 8 424.9677 563.196 Tm
(247 on whole blood lymphocytes of non-)Tj
-0.00011 Tc -10.9126 -1.25 Td
[(human primates [abstract]. )54.8 (Am J )17.7 (T)34.8 (ransplant 2001;1 Suppl 1:439.)]TJ
-2 -1.25 Td
[(31.)-625.1 (Maksymowych )17.7 (WP)110.7 (, )54.8 (Aspeslet L, )54.8 (Abel M, et al. Prevention and)]TJ
0 Tc 2 -1.25 Td
(treatment of antigen-induced arthritis by ISA)Tj
-0.00031 Tc 0 Tw 5.2 0 0 5.2 482.8288 530.556 Tm
(TX)Tj
0 Tc 0.02499 Tw 8 0 0 8 489.7591 533.196 Tm
(247, a novel)Tj
-19.0116 -1.25 Td
(calcineurin inhibitor [abstract]. J Rheumatol 2001;28 Suppl 63:92.)Tj
-0.00011 Tc -2 -1.25 Td
[(32.)-625.1 (Y)100 (atscof)17.7 (f R)54.8 (W)91.7 (, )54.8 (Abel MD, )54.8 (Aspeslet LJ, et al. ISA)]TJ
-0.00031 Tc 0 Tw 5.2 0 0 5.2 488.1047 510.556 Tm
(TX)Tj
0 Tc 0.0249 Tw 8 0 0 8 495.035 513.196 Tm
(247: Phase 1)Tj
-19.671 -1.25 Td
(clinical trial results of the novel calcineurin inhibitor [abstract]. )Tj
T*
(J Rheumatol 2001;28 Suppl 63:109.)Tj
-0.00011 Tc -2 -1.25 Td
[(33.)-625.1 (Henry ML. Cyclosporine and tacrolimus \(FK506\): a comparison of)]TJ
0 Tc 2 -1.25 Td
[(ef)17.8 (ficacy and safety profiles. Clin )17.8 (T)34.9 (ransplant 1999;13:209-20.)]TJ
-0.00011 Tc -2 -1.25 Td
[(34.)-625.1 (Leverson JP)110.7 (, Ness SA. Point mutations in v-Myb disrupt a)]TJ
0 Tc 2 -1.25 Td
(cyclophilin-catalyzed negative regulatory mechanism. Mol Cell)Tj
0 Tw T*
[(1998;1:203-1)36.9 (1.)]TJ
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(35.)-625.1 (Renoir JM, Mercier)19.7 (-Bodard C, Hof)17.7 (fman K, et al. Cyclosporin )54.8 (A)]TJ
0 Tc 2 -1.25 Td
(potentiates the dexamethasone-induced mouse mammary tumor)Tj
T*
[(virus-chloramphenicol acetyltransferase activity in LMCA)110.8 (T)-257.2 (cells: a)]TJ
T*
[(possible role for dif)17.8 (ferent heat shock protein-binding immunophilins)]TJ
T*
[(in glucocorticosteroid receptor)19.8 (-mediated gene expression. Proc Natl)]TJ
-0.00011 Tc T*
[(Sci USA)-220.2 (1995;92:4977-81.)]TJ
-2 -1.25 Td
[(36.)-625.1 (Suthanthiran M, Morris RE, Strom )17.7 (TB. Immunosuppressants:)]TJ
0 Tc 2 -1.25 Td
[(cellular and molecular mechanisms of action. )54.8 (Am J Kidney Dis)]TJ
0 Tw T*
(1996;28:159-72.)Tj
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(37.)-625.1 (Lo Russo )54.8 (AC, Passaquin P)110.7 (. Ef)17.7 (fect of cyclosporin )54.8 (A)-219.9 (and analogues)]TJ
0 Tc 2 -1.25 Td
(on cytosolic calcium and vasoconstriction: possible lack of)Tj
T*
[(relationship to immunosuppressive activity)64.9 (. Br J Pharmacol)]TJ
0 Tw T*
[(1996;1)36.9 (18:885-92.)]TJ
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(38.)-625.1 (Pascual M, Swinford RD, Ingelfinger JR, )17.7 (W)39.7 (illiams )17.7 (WW)91.7 (, Cosimi)]TJ
0 Tc 2 -1.25 Td
[(AB, )17.8 (T)69.8 (olkof)17.8 (f-Rubin N. Chronic rejection and chronic cyclosporin)]TJ
T*
[(toxicity in renal allografts. Immunol )17.8 (T)69.8 (oday 1998;19:514-9.)]TJ
-0.00011 Tc -2 -1.25 Td
[(39.)-625.1 (Usuda N, )54.8 (Arai H, Sasaki H, et al. Dif)17.7 (ferential subcellular localiza-)]TJ
0 Tc 2 -1.25 Td
(tion of neural isoforms of the catalytic subunit of calmodulin-)Tj
T*
(dependent protein phosphatase \(calcineurin\) in central nervous)Tj
-0.00011 Tc T*
[(system neurons: immunohistochemistry on formalin-fixed paraf)17.7 (fin)]TJ
0 Tc T*
(sections employing antigen retrieval by microwave irradiation. )Tj
T*
(J Histochem Cytochem 1996;44:8-13.)Tj
-2 -1.25 Td
[(40.)-625 (Mukai H, Kuno )17.7 (T)74 (, Chang CD, Lane B, Luly JR, )17.7 (T)69.8 (anaka C.)]TJ
2 -1.25 Td
(FKBP12-FK506 complex inhibits phosphatase activity of two)Tj
-0.00011 Tc T*
(mammalian isoforms of calcineurin irrespective of their subtrates or)Tj
0 Tc T*
[(activation mechanisms. J Biochem 1993;1)36.9 (13:292-8.)]TJ
-2 -1.25 Td
[(41.)-625 (Maini RN, Breedveld FC, Kalden JR, et al. )17.7 (Therapeutic ef)17.8 (ficacy of)]TJ
-0.00011 Tc 2 -1.25 Td
(multiple intravenous infusions of anti-tumor necrosis factor )Tj
/T1_0 1 Tf
0 Tc 0 Tw 24.25 0 Td
(\002)Tj
/TT1 1 Tf
0.02499 Tw -24.25 -1.25 Td
(monoclonal antibody combined with low-dose weekly methotrexate)Tj
T*
[(in rheumatoid arthritis. )54.9 (Arthritis Rheum 1998;41:1552-63.)]TJ
-0.00011 Tc -2 -1.25 Td
[(42.)-625.1 (Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P)110.7 (,)-0.1 ( Revillard)]TJ
2 -1.25 Td
[(JP)110.8 (. Immunosuppressive properties of methotrexate: )54.8 (Apoptosis and)]TJ
0 Tc T*
[(clonal deletion of activated peripheral )17.7 (T)-257.2 (cells. J Clin Invest)]TJ
0 Tw T*
(1998;102:322-8.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_1 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
78 0 obj
<>
endobj
114 0 obj
<>
endobj
134 0 obj
<>
endobj
75 0 obj
<>
endobj
84 0 obj
<>
endobj
79 0 obj
<>
endobj
107 0 obj
<>stream
HtV
PT}owY@('+.X8ЕdVB?IkOj&C(ɀhm4'kljVtNc&;~XLޙo=s=v! hV63ފ<,S"#?Ѫk)\P0ܿ_|'>l~yw5KSivvCÑ=@]ŋ{*s{EBK<y
xf
A}ݒ癠ZIM?{ypq4@:JB$i7"@E߳rwN0Jlg䕸G\p$~7$4c*!"1T|+PGb^:l-owF
Q(uܱX1q;y# tƬEȒ
V
xv%1* AX0"xkj02EX!vn+lb3ͬ,>-W!Vel(w`'ת"]M1Sk6m=bݣ>$#8'
DE(x?BDX)Vbi:H8-ΊK.$
9Ld)U2,ɈHz]6ٮA+ЊԎkek=YoWgU_]Gccc39%HH=H=<,}='-5eAI<Կ_߄>{s9&2Fqc0$KFP7CT n=}\-O_ᄃH!/+0]gTE*UmToበB*L-Tiʠ:3˯%_-28T\֬/TJmV:ðr]e)Uv&aYEP`tEF6ȞcFd_r+ML887V2;V)YY&䟽ixO_KgP'驲1kEsU.T
VtO6'LGzi^qƃPLO%?\QmwQS|g]hn͏:eb+0C,BقDMȧԧ7qiG\!J"($"軏hQ1bmDk>:OcbMKHyyWK j͕b)ϫ8=>nr/>&Y(1yRvg"Ϡ]Ǽ3N9RVCcb=I'7!9F;U4)ϲsL>ZU_VuG,%fܾ~BD
$6ˏΩ{t>"yD^,mن1Z;v6~̵έW[_QXKrtԲ)*>1Pm]'d)QR3zW<璏a-KLb1sX^̉P.jb6d?صjX}?{cwE].:}!nkyjRrvԌ9Q3b85v;;~Et;{5JUbՌjf}gYbb,+-u1؟ '=_Oe2O8_QLJdRj$K*(i5{Z*(Dyt_L-uRGǩM ˨Slm$ FZ6O˦mki21埙q^AMYn7\ $$7H @^